Sign in

Covid-19 vaccine unlikely before 2021, TB vaccine shows promise in reducing deaths

A parliamentary panel on Friday informed the government of India that a vaccine for Covid-19 is expected only by early next year.

Updated on: Jul 11, 2020, 10:12:26 IST
Hindustan Times, New Delhi | By
Share
Share via
  • facebook
  • twitter
  • linkedin
Copy link
  • copy link

Over six months into the coronavirus pandemic and the number of infected has crossed 12 million across the globe. Covid-19 has claimed more than 5 lakh lives globally while 7 million people have recovered from the deadly contagion worldwide. With a rapid surge in coronavirus cases across the globe, scientists and researchers are also ramping up effort to arrive at the potential Covid-19 vaccine.

IGilead Sciences Inc., Oxford experts and American biotech company Moderna are at the forefront of vaccine development for Covid-19. (AFP)
IGilead Sciences Inc., Oxford experts and American biotech company Moderna are at the forefront of vaccine development for Covid-19. (AFP)

Gilead Sciences Inc., Oxford experts and American biotech company Moderna are at the forefront of vaccine development for Covid-19. In an interview with HT, Oxford University professor Sunetra Gupta had said that by the end of this summer, “we should have proof that the vaccine works”.

Here are the latest developments on Covid-19 vaccine

• On Friday, Gilead Sciences Inc said an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill Covid-19 patients. It, however, added that rigorous clinical trials are needed to confirm ita benefit.

• Germany-based biotechnology company, BioNTech SE, could seek approval for its coronavirus vaccine by the end of the year, Wall Street Journal reported. The experimental vaccine, BNT162b1, showed promise against coronavirus in early-stage human testing and is expected to move into a large trial involving 30,000 participants this month, pending regulatory nod.

Also read: Psoriasis injection okayed for limited use to treat Covid-19 patients

• Moderna Inc is expecting to begin late-stage trials of its vaccine later this month. Its vaccine was among the first to be tested in humans in the US. In a small trial conducted on a group of healthy individuals, the vaccine was found to produce protective antibodies. The company has signed an agreement with Spain’s Laboratorios Farmacéuticos Rovi SA to scale up the manufacturing and production of its potential Covid-19 vaccine for markets outside the US.

• A tuberculosis vaccine routinely given to children in countries with high rates of that bacterial disease might be helping to reduce deaths from Covid-19, researchers reported on Thursday. The findings were published in the scientific journal Proceedings of the National Academy of Sciences.

• A parliamentary panel on Friday informed the government of India that a vaccine for Covid-19 is expected only by early next year. Presentations were given by the Department of Science and Technology, Department of Biotechnology, Council of Scientific and Industrial Research (CSIR) and the principal scientific adviser to the government before the Parliamentary Standing Committee on Science and Technology, Environment and Climate on the Centre’s Covid-19 preparedness.

(With inputs from agencies)

  • HT News Desk
    ABOUT THE AUTHOR
    HT News Desk

    Follow the latest breaking news, major developments and agenda-setting stories from India and around the world with the newsdesk at Hindustan Times. Operating round the clock, the desk brings together experienced editors, reporters and correspondents to deliver fast, accurate and contextual reporting across subjects that influence public policy, governance, business, society and international affairs. The HT News Desk covers politics, elections, government policies, the economy, business and markets, science and technology, the environment, law and order, infrastructure, education, climate issues and geopolitics, while closely tracking developments across states, institutions and global capitals. The team also leads coverage of major breaking news events, policy announcements, court proceedings, natural disasters, public emergencies and significant international developments. Reports published by the newsdesk are based on information gathered from reporters on the ground, official statements, government agencies, court records, regulatory filings, recognised institutions and other authoritative sources. Stories undergo editorial scrutiny and verification processes to ensure accuracy, fairness and relevance, and are updated as events evolve and additional information becomes available. Whether covering a key political decision in New Delhi, an economic policy shift affecting millions, a landmark court ruling or a major global event, the HT News Desk aims to provide readers with reliable, fact-based journalism that delivers not only the latest developments but also the context and analysis needed to understand their wider implications.Read More